Omnicell, Inc. OMCL is gaining from robust demand for its medication management and adherence automation solutions. Omnicell is well on track to achieve its 2025 targets, driven by several factors ...
Results exceed previously issued second quarter 2025 guidance for revenues, non-GAAP EBITDA and non-GAAP EPS Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance FORT WORTH, ...
Ratings for Omnicell (NASDAQ:OMCL) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their ...
Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance FORT WORTH, Texas--(BUSINESS WIRE)-- Omnicell, Inc. (“Omnicell,” “we,” “our ...
Analyst Stan Berenshteyn of Wells Fargo maintained a Hold rating on Omnicell (OMCL – Research Report), boosting the price target to $41.00. Stan Berenshteyn’s rating is based on a nuanced view of ...
Automating the future of patient care. That's Omnicell's goal for its new Innovation Lab, which is opening in Austin next week. Michael Garel, senior director of innovation at Omnicell, told the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results